Phase 1 Trial – PCM-075 Proves Safe as Colon Treatment


The number one disease in the world today is cancer. Cancer is a tumor that results in an uncontrolled division of abnormal cells.

Although there are treatment methods, no secure cure has been found. Those therapies don’t work for everyone, plus they don’t delete the cancer, they just silence it.

PCM-075 Proves Safe as Colon Treatment

There is always a risk of it showing again. That’s why this disease is so notorious and so dangerous.

Our lives would be that much easier if we found a cure that works for everyone and that permanently deletes this tumor from your system, but, we haven’t.

Maybe in the near future we will. With PCM-075, that future may come sooner rather than later. Before I start explaining what PCM-075 is, you need to understand its history and who developed it.

Companies Working Together With The Same Goal

We don’t see this very often. Usually, companies that have the same or similar agendas are rivals. Never will you see them working together on something.

As a matter of fact, the only thing that they have in common is that they want to bring each other down and take the market.

However, this is not the case with Trovagene and Nerviano. Both of them are conducting special medical researchers that are supposed to cure cancer.

With them teaming up together, the chances of finding the cure for cancer, and many other diseases, are much bigger.

What is Trovagene?

Trovagene[1] is a company that works in the field of biotechnology which does Precision Cancer Monitoring, or as you heard, PCM technology in tumor genomics. With their innovations they are targeting cancer patient populations.

Their technology in this field is advanced and it allows them to measure circulating tumor (ctDNA) that can be located in urine and blood. With this, they can predict patient’s response to cancer therapy.

At their accredited laboratory, CLIA/CAP, they offer their PCM technology with a clear goal ahead of them – developing precision cancer therapeutics.

On their official website they said that they believe in their ctDNA PCM technology and that they are experts in liquid biopsy testing which makes a significant advantage for the development of precision in cancer therapeutics.

What is Nerviano?

Full name – Nerviano Medical Sciences[2] (NMS). They are the biggest Italian company that researches and develops methods in the field of oncology.

For you to understand how big they are, it is enough to mention that their number of employees is around 500. NMS provides research and production that target the international market as well as the local.

They are working with many other companies and today, they represent a giant in their field of work.

As NMS says on their official website, they are able to manage the integrated chain of research and development path, which goes from pre-clinical phases to packaging the finished drug.

Collaboration of the Two

With two companies that share the common goal, I believe that we will get many useful drugs for many different diseases, which include cancer as well.

They are happy to be working together on this and are looking forward to extending their work even further.

Nerviano is the manufacturer for this finished drug, PCM-075, and Trovagene have all the rights to manufacture all the finished goods.

Both of them will receive great benefits from this. Nerviano will receive $2.0 million paid up front and will have their part in the sales that are yet to come.

However, I want to believe that this partnership didn’t occur because of the profit.

What Is PCM-075?

PCM-075 Therapy
PCM-075 is an inhibitor of the polo-like kinase – PLK1 – which is a protein that contributes to the development of certain cancer types.

The PCM-075 therapy has actually already proved to be safe in the Phase 1 clinical trial. The results from that trial aren’t published yet, but we can expect them to be, pretty soon.

This is a therapy for blood cancers, tumors and colon cancer.

The first group that has been using this drug under the supervision of scientists, were people around 62 years of age.

Researchers were monitoring sever key factors such as: body’s ability to absorb the drug, the dose that makes the drug toxic, and the maximum dose that is tolerated.

These patients received increased doses of PCM-075 for five days. This lasted for one cycle of 21 days.

The scientists also checked how the drug reacts in a tumor and if it has the ability to target PLK1 in tissue biopsies.

After the well conducted research, the results came and PCM-075 passed the test. However, it did show some side effects during this process. The most common side effects were thrombocytopenia and neutropenia.

  • Thrombocytopenia – Abnormal low number of blood platelets.
  • Neutropenia – Blood Disorder that results in low number of white blood cells.

These side effects were even expected, because of the PLK inhibitors which actually lead to cell death.

After this, Mark Erlander, Trovagene’s chief scientific officer, said that their main goal now is to explore the drug even further and assess additional precision cancer therapeutic opportunities.

Trovagene even made a bold statement saying that they believe PCM-075 has a bright future and a clear development path.

They completed the transfer of INDA – Investigational New Drug Application – from Nerviano to Trovagene and will conduct further researches in their own laboratories.

See More: Diagnosed With Colon Cancer? What Should You Know About Your Treatment


With all of this being said, it is clear that this innovative drug has a long way to go, however, its results are astonishing and represent a pinch of hope for human mankind.

Right now, everything that we, mere humans can do, is wait for further tests and hope for the best.

The PCM-075 drug is Treviano’s lead product candidate, meaning that they won’t give up on it easily and that there is a huge chance for further development.

The world can already feel the impact of the collaboration between two giants in the medical field. The best is yet to come.



Image Credits
Feature Image:
In-Post Image: